[{"orgOrder":0,"company":"Parallel Bio","sponsor":"Refactor Capital","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"","productType":"Undisclosed","year":"2022","type":"Financing","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Parallel Bio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Parallel Bio \/ Refactor Capital","highestDevelopmentStatusID":"2","companyTruncated":"Parallel Bio \/ Refactor Capital"}]

Find Clinical Drug Pipeline Developments & Deals by Parallel Bio

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Parallel Bio’s platform combines immune organoids with artificial intelligence and robotics to uniquely represent organoids as a population. Organoids are 3D, self-assembling models of human biology, or so-called mini organs.

                          Brand Name : Undisclosed

                          Molecule Type : Undisclosed

                          Upfront Cash : Undisclosed

                          December 20, 2022

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Technology

                          Highest Development Status : Discovery

                          Sponsor : Refactor Capital

                          Deal Size : $4.3 million

                          Deal Type : Financing

                          blank